Global Acute Myeloid Leukemia (AML) Therapeutics Market Size, Status and Forecast 2021-2027
Table of Content
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
- 1.2.2 Chemotherapy
- 1.2.3 Radiation therapy
- 1.2.4 Stem Cell Transplant
- 1.2.5 Targeted Therapy
- 1.2.6 Others
- 1.3 Market by Application
- 1.3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
- 1.3.2 Hospital
- 1.3.3 Clinics
- 1.3.4 Others
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Perspective (2016-2027)
- 2.2 Acute Myeloid Leukemia (AML) Therapeutics Growth Trends by Regions
- 2.2.1 Acute Myeloid Leukemia (AML) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
- 2.2.2 Acute Myeloid Leukemia (AML) Therapeutics Historic Market Share by Regions (2016-2021)
- 2.2.3 Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Regions (2022-2027)
- 2.3 Acute Myeloid Leukemia (AML) Therapeutics Industry Dynamic
- 2.3.1 Acute Myeloid Leukemia (AML) Therapeutics Market Trends
- 2.3.2 Acute Myeloid Leukemia (AML) Therapeutics Market Drivers
- 2.3.3 Acute Myeloid Leukemia (AML) Therapeutics Market Challenges
- 2.3.4 Acute Myeloid Leukemia (AML) Therapeutics Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Acute Myeloid Leukemia (AML) Therapeutics Players by Revenue
- 3.1.1 Global Top Acute Myeloid Leukemia (AML) Therapeutics Players by Revenue (2016-2021)
- 3.1.2 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Players (2016-2021)
- 3.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Players Covered: Ranking by Acute Myeloid Leukemia (AML) Therapeutics Revenue
- 3.4 Global Acute Myeloid Leukemia (AML) Therapeutics Market Concentration Ratio
- 3.4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Therapeutics Revenue in 2020
- 3.5 Acute Myeloid Leukemia (AML) Therapeutics Key Players Head office and Area Served
- 3.6 Key Players Acute Myeloid Leukemia (AML) Therapeutics Product Solution and Service
- 3.7 Date of Enter into Acute Myeloid Leukemia (AML) Therapeutics Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia (AML) Therapeutics Breakdown Data by Type
- 4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Historic Market Size by Type (2016-2021)
- 4.2 Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Type (2022-2027)
5 Acute Myeloid Leukemia (AML) Therapeutics Breakdown Data by Application
- 5.1 Global Acute Myeloid Leukemia (AML) Therapeutics Historic Market Size by Application (2016-2021)
- 5.2 Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
- 6.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size (2016-2027)
- 6.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type
- 6.2.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2021)
- 6.2.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2022-2027)
- 6.2.3 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2027)
- 6.3 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application
- 6.3.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2021)
- 6.3.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2022-2027)
- 6.3.3 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2027)
- 6.4 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
- 6.4.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2016-2021)
- 6.4.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2022-2027)
- 6.4.3 United States
- 6.4.3 Canada
7 Europe
- 7.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size (2016-2027)
- 7.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type
- 7.2.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2021)
- 7.2.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2022-2027)
- 7.2.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2027)
- 7.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application
- 7.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2021)
- 7.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2022-2027)
- 7.3.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2027)
- 7.4 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
- 7.4.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2016-2021)
- 7.4.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2022-2027)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic
8 Asia-Pacific
- 8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size (2016-2027)
- 8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type
- 8.2.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2021)
- 8.2.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2022-2027)
- 8.2.3 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2027)
- 8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application
- 8.3.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2021)
- 8.3.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2022-2027)
- 8.3.3 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2027)
- 8.4 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region
- 8.4.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2016-2021)
- 8.4.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2022-2027)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 Southeast Asia
- 8.4.7 India
- 8.4.8 Australia
9 Latin America
- 9.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size (2016-2027)
- 9.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type
- 9.2.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2021)
- 9.2.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2022-2027)
- 9.2.3 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2027)
- 9.3 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application
- 9.3.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2021)
- 9.3.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2022-2027)
- 9.3.3 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2027)
- 9.4 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
- 9.4.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2016-2021)
- 9.4.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2022-2027)
- 9.4.3 Mexico
- 9.4.4 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size (2016-2027)
- 10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type
- 10.2.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2021)
- 10.2.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2022-2027)
- 10.2.3 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2016-2027)
- 10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application
- 10.3.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2021)
- 10.3.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2022-2027)
- 10.3.3 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2016-2027)
- 10.4 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
- 10.4.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2016-2021)
- 10.4.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2022-2027)
- 10.4.3 Turkey
- 10.4.4 Saudi Arabia
- 10.4.5 UAE
11 Key Players Profiles
- 11.1 Bristol-Myers Squibb
- 11.1.1 Bristol-Myers Squibb Company Details
- 11.1.2 Bristol-Myers Squibb Business Overview
- 11.1.3 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Introduction
- 11.1.4 Bristol-Myers Squibb Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2016-2021)
- 11.1.5 Bristol-Myers Squibb Recent Development
- 11.2 Novartis
- 11.2.1 Novartis Company Details
- 11.2.2 Novartis Business Overview
- 11.2.3 Novartis Acute Myeloid Leukemia (AML) Therapeutics Introduction
- 11.2.4 Novartis Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2016-2021)
- 11.2.5 Novartis Recent Development
- 11.3 Roche
- 11.3.1 Roche Company Details
- 11.3.2 Roche Business Overview
- 11.3.3 Roche Acute Myeloid Leukemia (AML) Therapeutics Introduction
- 11.3.4 Roche Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2016-2021)
- 11.3.5 Roche Recent Development
- 11.4 Genmab
- 11.4.1 Genmab Company Details
- 11.4.2 Genmab Business Overview
- 11.4.3 Genmab Acute Myeloid Leukemia (AML) Therapeutics Introduction
- 11.4.4 Genmab Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2016-2021)
- 11.4.5 Genmab Recent Development
- 11.5 GlaxoSmithKline Pharmaceuticals
- 11.5.1 GlaxoSmithKline Pharmaceuticals Company Details
- 11.5.2 GlaxoSmithKline Pharmaceuticals Business Overview
- 11.5.3 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Introduction
- 11.5.4 GlaxoSmithKline Pharmaceuticals Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2016-2021)
- 11.5.5 GlaxoSmithKline Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
Description
Acute Myeloid Leukemia (AML) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Acute Myeloid Leukemia (AML) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Chemotherapy
Radiation therapy
Stem Cell Transplant
Targeted Therapy
Others
Segment by Application
Hospital
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb
Novartis
Roche
Genmab
GlaxoSmithKline Pharmaceuticals
Genmab